Medtronic (NYSE:MDT) Releases FY 2026 Earnings Guidance

Medtronic (NYSE:MDT) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 5.620-5.660 for the period, compared to the consensus earnings per share estimate of 5.640. The company issued revenue guidance of -, compared to the consensus revenue estimate of $36.0 billion.

Medtronic Stock Down 1.3%

NYSE:MDT opened at $99.57 on Tuesday. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. Medtronic has a 12-month low of $79.55 and a 12-month high of $106.33. The stock’s fifty day simple moving average is $99.25 and its 200-day simple moving average is $96.53. The firm has a market capitalization of $127.65 billion, a P/E ratio of 26.84, a P/E/G ratio of 2.62 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.33 by $0.03. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts expect that Medtronic will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Royal Bank Of Canada boosted their price objective on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. Leerink Partners set a $120.00 price target on shares of Medtronic and gave the company an “outperform” rating in a report on Wednesday, November 19th. JPMorgan Chase & Co. raised their price objective on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Robert W. Baird set a $103.00 target price on Medtronic in a report on Tuesday, December 16th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $110.00 price target on shares of Medtronic in a report on Wednesday, November 19th. Sixteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $111.21.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 results beat expectations — non‑GAAP EPS $1.36 vs. $1.33 expected and revenue $9.02B vs. $8.89B consensus; management provided slides and a press release highlighting the outperformance. Press Release
• Positive Sentiment: Robust demand for cardiac devices and diabetes monitors helped drive the beat — analysts note strength in heart devices and ablation portfolio expansion as durable revenue drivers. Reuters: Demand Drive
• Positive Sentiment: Product and regulatory wins: FDA clearances (Hugo™ robotic system, Stealth AXiS™) plus CE mark and U.S. pivotal trial starts for other platforms; first U.S. Hugo commercial case reported — these expand addressable markets and support future growth. PR Newswire: Q3 Highlights
• Neutral Sentiment: FY2026 EPS guidance set to $5.620–5.660, which essentially aligns with the consensus (~$5.64) — guidance is not a material beat or miss, so it’s unlikely to sharply change expectations.
• Neutral Sentiment: Analyst commentary and previews are focusing on capital allocation and margin trajectory as investors digest results; these narratives may influence sentiment but not immediate fundamentals. Kalkine Media Benzinga Preview
• Negative Sentiment: Profit fell on a GAAP basis as costs and investments rose — higher spending to support growth and new product rollouts weighed on margins, a concern for investors focused on near‑term profitability. WSJ: Profit Falls
• Negative Sentiment: Antitrust/regulatory risk flagged in recent coverage — potential headwind if competitive or regulatory actions slow adoption of new surgical/spine products. Yahoo Finance: Antitrust

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MDT. Acumen Wealth Advisors LLC acquired a new stake in Medtronic in the 4th quarter valued at approximately $29,000. Imprint Wealth LLC bought a new position in shares of Medtronic during the 3rd quarter worth approximately $31,000. JPL Wealth Management LLC acquired a new stake in shares of Medtronic in the third quarter valued at approximately $40,000. Chapman Financial Group LLC bought a new stake in shares of Medtronic in the second quarter worth $37,000. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Medtronic by 96.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 454 shares of the medical technology company’s stock worth $44,000 after purchasing an additional 223 shares during the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).